Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322645 | 0.90 | POLB (0.44) | POLBTAS1R3TAS1R1ENPP1P2RY1 | |
| SCHEMBL25582525 | 0.88 | RNASEL (0.57) | POLBTAS1R3TAS1R1RNASELP2RY1 | |
| SCHEMBL24325561 | 0.87 | POLB (0.53) | POLBRNASELENPP1P2RY1 | |
| SCHEMBL17122136 | 0.84 | POLB (0.56) | POLBP2RX3P2RX2RNASELENPP1 | |
| SCHEMBL21539898 | 0.82 | ALDH1A1 (0.51) | POLBTAS1R3TAS1R1RNASELP2RY1 | |
| SCHEMBL21540035 | 0.82 | ALDH1A1 (0.51) | POLBTAS1R3TAS1R1RNASELP2RY1 | |
| SCHEMBL21539867 | 0.82 | ALDH1A1 (0.51) | POLBTAS1R3TAS1R1RNASELP2RY1 | |
| SCHEMBL21895950 | 0.81 | RNASEL (0.49) | POLBRNASEL | |
| SCHEMBL17948732 | 0.81 | RNASEL (0.49) | POLBRNASEL | |
| SCHEMBL16574745 | 0.81 | RNASEL (0.49) | POLBRNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | POLB 31/4885P2RX3 1370/4885P2RX2 1458/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | POLB 31/4885P2RX3 1370/4885P2RX2 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.